Skip to main content

Market Overview

30 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Share:

Gainers

  • Solid Biosciences, Inc. (NASDAQ: SLDB) stock surged 33.8% to $6.42 during Wednesday's pre-market session. The market cap seems to be at $508.2 million. The most recent rating by Nomura, on November 13, is at Buy, with a price target of $6.00.
  • Dare Bioscience, Inc. (NASDAQ: DARE) stock rose 18.4% to $0.95. The market cap stands at $13.5 million.
  • ASLAN Pharmaceuticals, Inc. (NASDAQ: ASLN) stock surged 15.9% to $2.70. The market cap stands at $33.2 million. The most recent rating by H.C. Wainwright, on December 10, is at Buy, with a price target of $5.00.
  • Atossa Genetics, Inc. (NASDAQ: ATOS) stock surged 11.3% to $1.58. The market value of their outstanding shares is at $14.5 million.
  • Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) stock moved upwards by 10.4% to $5.10. The market value of their outstanding shares is at $219.6 million. The most recent rating by JMP Securities, on October 18, is at Market Outperform, with a price target of $16.00.
  • Achieve Life Sciences, Inc. (NASDAQ: ACHV) stock increased by 6.0% to $0.52. The market cap seems to be at $10.4 million.
  • Cellectis, Inc. (NASDAQ: CLLS) shares rose 5.0% to $18.94. The market cap stands at $497.0 million.
  • Seelos Therapeutics, Inc. (NASDAQ: SEEL) shares increased by 4.7% to $1.34. The market cap stands at $24.2 million.
  • ObsEva, Inc. (NASDAQ: OBSV) stock moved upwards by 4.5% to $3.01. The market cap seems to be at $337.6 million. The most recent rating by RBC Capital, on December 10, is at Outperform, with a price target of $19.00.
  • SCYNEXIS, Inc. (NASDAQ: SCYX) shares surged 3.1% to $0.77. The market cap seems to be at $67.1 million.
  • Verastem Oncology, Inc. (NASDAQ: VSTM) stock moved upwards by 2.4% to $1.30. The market cap seems to be at $81.0 million.
  • Eli Lilly, Inc. (NYSE: LLY) shares increased by 1.5% to $127.15. The market value of their outstanding shares is at $112.6 billion. The most recent rating by Morgan Stanley, on December 18, is at Overweight, with a price target of $150.00.
  • Correvio Pharma, Inc. (NASDAQ: CORV) stock increased by 1.4% to $0.39. The market cap stands at $101.2 million. According to the most recent rating by H.C. Wainwright, on December 11, the current rating is at Neutral.
  • Aurora Cannabis, Inc. (NYSE: ACB) shares moved upwards by 1.3% to $2.36. The market cap seems to be at $2.6 billion. The most recent rating by Piper Jaffray, on October 22, is at Neutral, with a price target of $4.00.
  • Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) stock rose 1.3% to $0.31. The market cap stands at $64.8 million.
  • Novartis, Inc. (NYSE: NVS) stock moved upwards by 1.1% to $94.31. The market cap seems to be at $208.7 billion.

 

Losers

  • Homology Medicines, Inc. (NASDAQ: FIXX) shares plummeted 21.8% to $17.00 during Wednesday's pre-market session. The market cap seems to be at $577.1 million. According to the most recent rating by Oppenheimer, on November 01, the current rating is at Perform.
  • Aduro Biotech, Inc. (NASDAQ: ADRO) stock fell 12.2% to $1.01. The market cap seems to be at $91.7 million. According to the most recent rating by William Blair, on December 18, the current rating is at Market Perform.
  • Zafgen, Inc. (NASDAQ: ZFGN) shares plummeted 10.1% to $0.74. The market cap seems to be at $27.6 million.
  • NantKwest, Inc. (NASDAQ: NK) shares decreased by 4.2% to $3.66. The market cap seems to be at $103.2 million.
  • Sorrento Therapeutics, Inc. (NASDAQ: SRNE) stock plummeted 3.2% to $3.90. The market value of their outstanding shares is at $215.6 million. The most recent rating by JMP Securities, on October 07, is at Market Outperform, with a price target of $21.00.
  • Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) stock declined 2.4% to $0.37. The market value of their outstanding shares is at $31.0 million.
  • Genmab, Inc. (NASDAQ: GMAB) shares decreased by 2.2% to $21.85. The market value of their outstanding shares is at $14.1 billion. The most recent rating by HC Wainwright & Co., on October 16, is at Buy, with a price target of $25.00.
  • DBV Technologies, Inc. (NASDAQ: DBVT) stock decreased by 2.1% to $8.73. The market cap seems to be at $676.0 million. The most recent rating by Citigroup, on December 16, is at Buy, with a price target of $14.00.
  • Acasti Pharma, Inc. (NASDAQ: ACST) stock plummeted 1.7% to $2.36. The market value of their outstanding shares is at $158.4 million. The most recent rating by B. Riley FBR, on November 18, is at Buy, with a price target of $8.00.
  • Venus Concept, Inc. (NASDAQ: VERO) shares declined 1.5% to $5.85. The market cap seems to be at $16.3 million.
  • VIVUS, Inc. (NASDAQ: VVUS) shares plummeted 1.5% to $2.66. The market value of their outstanding shares is at $36.1 million.
  • Guardion Health Sciences, Inc. (NASDAQ: GHSI) shares fell 1.5% to $0.21. The market cap stands at $20.3 million.
  • Qiagen, Inc. (NYSE: QGEN) stock decreased by 1.3% to $40.72. The market cap seems to be at $6.7 billion. The most recent rating by Commerzbank, on November 18, is at Buy, with a price target of $48.00.
  • BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) stock fell 1.2% to $3.19. The market cap seems to be at $439.0 million. According to the most recent rating by Bank of America, on November 15, the current rating is at Buy.
 

Related Articles (ACB + ACHV)

View Comments and Join the Discussion!

Posted-In: Healthcare Stocks Pre-Market MoversNews Movers & Shakers Pre-Market Outlook Markets Movers Trading Ideas General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com